Prevail Therapeutics Inc.
Prevail Therapeutics Inc. (PRVL): 7 pipeline candidates · ~17 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
16.7 months
D/E 0.19 · 0% dilution
Lead: Phase 1/Phase 2
7 candidates
N/A
N/A
A transparent, data-derived signal for Prevail Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$81.8M
Quarterly Burn
$16.6M
Runway
16.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
Frequently asked questions
How many drug candidates are in Prevail Therapeutics Inc.'s pipeline?
Prevail Therapeutics Inc. (PRVL) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Prevail Therapeutics Inc.'s lead drug candidate?
Prevail Therapeutics Inc.'s most advanced tracked candidate is ly3884961 (Phase 1/Phase 2) for Parkinson Disease; Gaucher Disease; Gaucher Disease, Type 2.
What is Prevail Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Prevail Therapeutics Inc. has approximately 16.7 months of cash runway.
Who is the CEO of Prevail Therapeutics Inc.?
Asa Abeliovich, M.D. is the chief executive officer of Prevail Therapeutics Inc. (PRVL).
Get the full picture on Prevail Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.